Cellectar Biosciences, Inc.
CLRB
$2.36
-$0.15-5.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 15.09% | 51.12% | 62.38% | 45.11% | 60.56% |
| Total Depreciation and Amortization | -81.73% | -26.74% | -20.57% | -6.25% | 8.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 106.45% | 201.19% | -300.32% | -147.89% | -169.52% |
| Change in Net Operating Assets | 136.26% | -81.19% | -4,718.76% | 10.24% | -1,165.32% |
| Cash from Operations | 57.39% | 51.42% | 35.83% | 23.44% | -13.10% |
| Capital Expenditure | 88.74% | 94.34% | 80.21% | 93.24% | 90.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 88.74% | 94.34% | 80.21% | 93.24% | 90.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -25.79% | -78.78% | -90.43% | -70.34% | -73.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -25.79% | -78.78% | -87.00% | -70.34% | -73.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 78.73% | -173.54% | -242.10% | -171.58% | -195.53% |